ORION OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.48 EUR | +1.38% |
|
+0.37% | -4.56% |
| May. 07 | Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025 | CI |
| Apr. 26 | Orion Corporation Announces Appointments to Nomination Committee | CI |
| Sales 2024 * | 1.38B 1.49B | Sales 2025 * | 1.45B 1.57B | Capitalization | 5.29B 5.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 242M 262M | Net income 2025 * | 250M 271M | EV / Sales 2024 * | 3.81 x |
| Net cash position 2024 * | 46.22M 50.13M | Net cash position 2025 * | 3.2M 3.47M | EV / Sales 2025 * | 3.64 x |
| P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
21.1
x | Employees | 3,698 |
| Yield 2024 * |
4.47% | Yield 2025 * |
4.56% | Free-Float | 89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orion Oyj
More press releases
More news
| 1 day | +1.38% | ||
| 1 week | +0.37% | ||
| 1 month | +4.72% | ||
| 3 months | +2.38% | ||
| 6 months | +2.71% | ||
| Current year | -4.56% |
1 week
36.15
37.80
1 month
35.5838.20
Current year
31.8645.29
1 year
31.8645.29
3 years
31.8655.16
5 years
28.7655.16
10 years
22.5758.50
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 98-12-31 |
| Chief Operating Officer | - | 15-12-31 | |
Outi Vaarala
CTO | Chief Tech/Sci/R&D Officer | 62 | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-03-24 | |
| Director/Board Member | 61 | 17-03-21 | |
| Director/Board Member | 54 | 22-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 664 M€ | +9.24% | ||
| 2.87% | 473 M€ | +5.85% | ||
| 0.35% | 1,083 M€ | +4.80% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 37.48 | +1.38% | 896,225 |
| 24-05-30 | 36.97 | +1.26% | 102,477 |
| 24-05-29 | 36.51 | -1.35% | 177,153 |
| 24-05-28 | 37.01 | -1.52% | 206,846 |
| 24-05-27 | 37.58 | +0.64% | 115,774 |
Delayed Quote Nasdaq Helsinki, May 31, 2024 at 11:29 am EDT
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
37.48
EUR
Average target price
39
EUR
Spread / Average Target
+4.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.56% | 5.73B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- ORNBV Stock
